Sevelamer-Vista tab. p / captivity. obol. 800 mg No. 180 ***

Sevelamer-Vista it is shown for treatment of a hyperphosphatemia at the adult patients who are on a hemodialysis or peritoneal dialysis.

Sevelamer-Vista it is also shown for control of a hyperphosphatemia at adult patients with a chronic disease of kidneys which are not on dialysis, with phosphorus content in blood serum of ≥1.78 mmol/l.

Sevelamer-Vista should be applied as a part of the complex therapy including calcic additive, 1.25 _{3 dihydroxyvitamin D} or one of its analogs to control of development of a renal osteodystrophy.

Structure

Active ingredient: sevelamer;

1 tablet, coated, contains a sevelamer of a carbonate 800 mg;

Excipients: lactose monohydrate, silicon dioxide colloidal stearate of zinc;

covering Components: a gipromelloza (15 MPa·c), a gipromelloza (5 MPa·c), diacetylized monoglycerides, the water purified.

Contraindication

Hypersensitivity to active ingredient or to any of medicament components.

Hypophosphatemia.

Intestinal impassability (obstruction).

Route of administration

For oral administration. It is necessary to swallow of tablets entirely, without crushing, without dividing and without chewing. Tablets should be applied with food, but not on an empty stomach.

Feature of use

Pregnant

advantage/risk for mother and a fruit Can be appointed to pregnant women only by strict need and after careful assessment of a ratio.

Children

it is not intended for use for children.

has no

or has very insignificant ability to influence speed of response at control of motor transport or work with other mechanisms.

Overdose

Symptoms which are observed at overdose similar to the side reactions described in the section "Side reactions" include mainly a constipation and other known gastrointestinal disorders.

corresponding symptomatic treatment.

Side effects

from digestive tract: very often - nausea, vomiting, pain in an upper part of a stomach, a constipation; often - diarrhea, dyspepsia, a meteorism, an abdominal pain.

Patients accepting antiarrhytmic medicines for control of arrhythmias and anticonvulsant medicines for prevention of attack in clinical trials were not attracted by

. Therefore it is necessary to appoint with care Sevelamer-Vista to the patients accepting antiarrhytmic medicines.

Storage conditions

to Store

in original packing at a temperature not above 25 °C.

to Store

out of children's reach.

Expiration date - 3 years.